Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)

Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description

This study involves taking a study drug called selpercatinib. The overall goal of this study is to find out how effective the study drug is in combination with radioactive iodine (I-131) in treating people with thyroid cancer. The study drug will be given in combination with treatments you will receive as part of your regular cancer care (I-131 and thyrotropin alfa).

What to expect
The study will enroll male and female patients between 12 and 40 years of age that have been diagnosed with RET fusion-positive radioiodine-refractory thyroid cancer. As a participant in this research, you will:
  • Receive a study drug called selpercatinib in combination with therapy you would receive as part of your regular cancer care (I-131 and thyrotropin alfa (rhTSH))
  • Complete frequent clinic visits at CHOP
  • Complete medication diaries
  • Have blood tests performed as part of your regular cancer care
  • Have tissue collected if you have a biopsy as part of your regular cancer care
  • Have MRIs and X-rays if you are under the age of 18
  • Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
  • Have periodic EKGs and echocardiograms as part of your regular cancer care

Related specialties

Related conditions
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.